Deutsche Bank AG Trims Stock Position in Lifecore Biomedical, Inc. (NASDAQ:LFCR)

Deutsche Bank AG cut its position in shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR - Free Report) by 91.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 25,433 shares of the company's stock after selling 290,286 shares during the period. Deutsche Bank AG owned approximately 0.07% of Lifecore Biomedical worth $189,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bridgeway Capital Management LLC boosted its stake in Lifecore Biomedical by 2.5% during the fourth quarter. Bridgeway Capital Management LLC now owns 78,800 shares of the company's stock valued at $585,000 after buying an additional 1,900 shares during the last quarter. Bank of America Corp DE boosted its stake in Lifecore Biomedical by 25.3% during the fourth quarter. Bank of America Corp DE now owns 33,507 shares of the company's stock valued at $249,000 after buying an additional 6,776 shares during the last quarter. 325 Capital LLC boosted its stake in Lifecore Biomedical by 57.9% during the fourth quarter. 325 Capital LLC now owns 2,162,466 shares of the company's stock valued at $16,067,000 after buying an additional 792,681 shares during the last quarter. Northern Trust Corp boosted its stake in Lifecore Biomedical by 14.5% during the fourth quarter. Northern Trust Corp now owns 221,498 shares of the company's stock valued at $1,646,000 after buying an additional 28,019 shares during the last quarter. Finally, MetLife Investment Management LLC bought a new position in Lifecore Biomedical during the fourth quarter valued at approximately $108,000. 83.36% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, William Blair assumed coverage on Lifecore Biomedical in a research note on Wednesday, May 21st. They issued an "outperform" rating for the company.

Insider Buying and Selling at Lifecore Biomedical

In other Lifecore Biomedical news, major shareholder Aron R. English sold 15,847 shares of Lifecore Biomedical stock in a transaction dated Wednesday, May 7th. The stock was sold at an average price of $7.01, for a total transaction of $111,087.47. Following the completion of the transaction, the insider now owns 1,714,070 shares in the company, valued at approximately $12,015,630.70. This trade represents a 0.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In the last quarter, insiders sold 1,485,182 shares of company stock worth $9,824,031. Insiders own 32.20% of the company's stock.

Lifecore Biomedical Stock Performance

LFCR traded up $0.01 on Wednesday, reaching $6.88. 109,093 shares of the stock were exchanged, compared to its average volume of 240,700. The company's 50-day moving average price is $6.52 and its 200 day moving average price is $6.57. Lifecore Biomedical, Inc. has a fifty-two week low of $3.68 and a fifty-two week high of $7.99. The company has a debt-to-equity ratio of 9.21, a current ratio of 2.32 and a quick ratio of 1.21. The firm has a market capitalization of $254.73 million, a PE ratio of -12.29 and a beta of 0.65.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last issued its quarterly earnings results on Thursday, April 3rd. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.05). Lifecore Biomedical had a negative return on equity of 315.23% and a negative net margin of 12.52%. The firm had revenue of $35.15 million for the quarter, compared to analyst estimates of $33.23 million. As a group, sell-side analysts forecast that Lifecore Biomedical, Inc. will post -0.91 EPS for the current fiscal year.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.